EC Gynaecology

Editorial Volume 11 Issue 8 - 2022

Immuno-Metabolic Perspectives in the Care of Climacteric Women

Ana Quevedo, Joao Pedro Esteves, Marilia Esteves and Claudio Lera Orsatti*

Department Health Science, Oeste Paulista University, UNOESTE, Jau, SP, Brazil

*Corresponding Author: Claudio Lera Orsatti, Department Health Science, University of Oeste Paulista, UNOESTE, Jau, SP, Brazil.
Received: July 04, 2022; Published: July 27, 2022

Cardiovascular diseases (CVD) continue to be one of the main causes of death in the population. “Middle-aged” people (between 45 and years old) and elderly people (> 64 years old) shoulder most of the burden of CVD. In this sense, it is imperative to understand the mechanisms underlying its pathogenesis in an attempt to develop efficient therapies and reduce the burden of CVD [1].

  1. Benjamin EJ., et al. “Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association”. Circulation (2019): 139.
  2. Mosca L., et al. “Evidence-Based Guidelines for Cardiovascular Disease Prevention in Women: 2007 Update”. Circulation 115 (2007): 1481-1501.
  3. El Khoudary SR., et al. “Menopause Transition and Cardiovascular Disease Risk: Implications for Timing of Early Prevention: A Scientific Statement From the American Heart Association”. Circulation (2020): 142.
  4. Geraci A., et al. “Sarcopenia and Menopause: The Role of Estradiol”. Frontiers in Endocrinology 12 (2021): 682012.
  5. Polotsky H and Polotsky A. “Metabolic Implications of Menopause”. Seminars in Reproductive Medicine 28 (2010): 426-434.
  6. Rodríguez-Iturbe B and Johnson R. “Heat shock proteins and cardiovascular disease”. Physiology International 105 (2018): 19-37.
  7. Zilaee M., et al. “Heat shock proteins and cardiovascular disease”. Advances in Clinical Chemistry 64 (2014): 73-115.
  8. Seibert TA., et al. “Serum Heat Shock Protein 27 Levels Represent a Potential Therapeutic Target for Atherosclerosis”. Journal of the American College of Cardiology 62 (2013): 1446-1454.
  9. Rayner K., et al. “Heat shock protein 27: clue to understanding estrogen-mediated atheroprotection?” Trends in Cardiovascular Medicine 20 (2010): 54-58.
  10. Park HK., et al. “Expression of Heat Shock Protein 27 in Human Atherosclerotic Plaques and Increased Plasma Level of Heat Shock Protein 27 in Patients With Acute Coronary Syndrome”. Circulation 114 (2006): 886-893.
  11. Lepedda AJ., et al. “A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries”. Atherosclerosis 203 (2009): 112-118.
  12. Liang W., et al. “Distinctive proteomic profiles among different regions of human carotid plaques in men and women”. Scientific Reports 6 (2016): 26231.
  13. Inia JA and O’Brien ER. “Role of Heat Shock Protein 27 in Modulating Atherosclerotic Inflammation”. Journal of Cardiovascular Translational Research 14 (2021): 3-12.
  14. Rayner K., et al. “Heat Shock Protein 27 Protects Against Atherogenesis via an Estrogen-Dependent Mechanism: Role of Selective Estrogen Receptor Beta Modulation”. Arteriosclerosis, Thrombosis, and Vascular Biology 29 (2009): 1751-1756.
  15. Rayner K., et al. “Extracellular Release of the Atheroprotective Heat Shock Protein 27 Is Mediated by Estrogen and Competitively Inhibits acLDL Binding to Scavenger Receptor-A”. Circulation Research 103 (2008): 133-141.
  16. Batulan Z., et al. “Extracellular Release and Signaling by Heat Shock Protein 27: Role in Modifying Vascular Inflammation”. Frontiers in Immunology 7 (2016): 285.

Claudio Lera Orsatti., et al. Immuno-Metabolic Perspectives in the Care of Climacteric Women. EC Gynaecology 11.8 (2022): 01-02.